Recent changes in the landscape of combination RAS blockade

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 11, 2009, Pages 1373-1384

  Epstein, Benjamin J ^a,b   Smith, Steven M ^a   Choksi, Rushab ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b East Coast Institute for Research   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Blood pressure; Renin angiotensin system

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BENAZEPRIL PLUS VALSARTAN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANDESARTAN HEXETIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; INOTROPIC AGENT; IRBESARTAN; ISOSORBIDE DINITRATE; LOSARTAN; PLACEBO; POTASSIUM; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ACUTE HEART INFARCTION; ADD ON THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COUGHING; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROTOXICITY; POTASSIUM BLOOD LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPEATED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FUMARATES; HEART FAILURE; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 73349128134     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.127     Document Type: Review

References (66)

1. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet 369, 1208-1219 (2007).
2. Yusuf S, Sleight P, Pogue J et al.; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342,145-153 (2000).
3. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD; The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 329, 1456-1462 (1993).
4. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355, 253-259 (2000).
5. Parving HH, Lehnert H, Bröchner-Mortensen J et al.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. N. Engl. J. Med. 345, 870-878 (2001).
6. Sever PS, Poulter NR, Elliott WJ. Blood pressure reduction is not the only determinant of outcome. Circulation 113, 2754-2772 (2006). • Comprehensive overview of the effects of antihypertensive drugs beyond blood pressure lowering.
7. Biollaz J, Brunner HR, Gavras I et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J. Cardiovasc. Pharmacol. 4, 966-972 (1982).
8. Ubaid-Girioli S, Ferreira-Melo SE, Souza LA et al. Aldosterone escape with diuretic or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy in patients with mild to moderate hypertension. J. Clin. Hypertens. 9, 770-774 (2007).
9. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int. J. Clin. Pract. 61, 1461-1468 (2007).
10. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008). • Landmark study evaluating the effect of combination renin-angiotensin system blockade in more than 25,000 high-risk patients.
11. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362, 767-771 (2003). • Landmark clinical trial demonstrating the effects of combination renin-angiotensin system blockade in patients with chronic heart failure.
12. Bakris GL, Ruilope L, Locatelli F et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int. 72, 879-885 (2007). • Well-conducted evaluation of combination renin-angiotensin system blockade in hypertensive patients evaluating renal end points.
13. Ravandi A, Teo KK. Blocking the renin-angiotensin system: dual- versus monotherapy. Expert Rev. Cardiovasc. Ther. 7, 667-674 (2009).
14. Sever PS, Gradman AH, Azizi M. Managing cardiovascular and renal risk: the potential of direct renin inhibition. J. Renin Angiotensin Aldosterone Syst. 10, 65-76 (2009).
15. Epstein BJ, Gums JG. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations. Ann. Pharmacother. 39, 470-480 (2005).
16. Gradman KH, Kad R. Renin inhibition in hypertension. J. Am. Coll. Cardiol. 51, 519-528 (2008). • Comprehensive review of the role of renin inhibition in the management of hypertension.
17. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 351, 1693-1697 (1998).
18. Ennezat PV, Berlowitz M, Sonnenblick EH, Le Jemtel TH. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr. Cardiol. Rep. 2, 258-262 (2000).
19. Bosch J, Lonn E, Pogue J et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 112, 1339-1346 (2005).
20. Hall AS, Murray GD, Ball SG. Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy. Lancet 349, 1493-1497 (1997).
21. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, doubleblind study. J. Hum. Hypertens. PMID: 19458624 ( 2009) (Epub ahead of print).
22. Drummond W, Munger MA, Rafique Essop M, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J. Clin. Hypertens. 9, 742-750 (2007).
23. Weinberger MH, Andersen K, Constance CM et al. Aliskiren-based therapy provides long-term suppression of plasma renin activity that persists after treatment withdrawal in patients with hypertension. J. Am. Coll. Cardiol. 49(9 Suppl. A), 390A-391A (2007) (Abstract 1020-1168).
24. Philipp T, Schmieder RE, Guerediaga J et al. Aliskiren-based therapy provides long-term renin system suppression in patients with hypertension in a 52-wk comparator trial with hydrochlorothiazidebased therapy. J. Clin. Hypertension 9(Suppl. A), A175 Poster P-421 (2007).
25. Data on file. Novartis Pharmaceuticals.
26. Werner C, Baumhäkel M, Teo KK et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin. Res. Cardiol. 97, 418-431 (2008).
27. Schulman IH, Raij L. The angiotensin II type 2 receptor: what is its clinical significance? Curr. Hypertens. Rep. 10, 188-193 (2008).
28. Lazartigues E, Feng Y, Lavoie JL. The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. Curr. Pharm. Des. 13, 1231-1245 (2007).
29. Loriga G, Vidili G, Ruggenenti P, Faedda R, Sanna M, Satta AE. Renal hemodynamics and renoprotection. Nephron. Clin. Pract. 110, c213-c219 (2008).
30. Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int. J. Clin. Pract. 61, 1461-1468 (2007).
31. Nguyen G, Danser AH. Prorenin and (pro) renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 93, 557-563 (2008). • Elegant review of the role of renin-angiotensin system with a focus on renin and its receptor in the pathophysiology of cardiovascular disease.
32. Sealey JE, Laragh JH. Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises. Am. J. Hypertens. 22, 112-121 (2009).
33. Stanton AV, Dicker P, O'Brien ET et al. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am. J. Hypertens. PMID: 19556972 (2009) (Epub ahead of print).
34. Danser AH, Charney A, Feldman DL, Nussberger J, Fisher N, Hollenberg N. The renin rise with aliskiren: it's simply stoichiometry. Hypertension 51, e27-e28 (2008).
35. Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52, 130-136 (2008).
36. Doulton TWR, He FJ, Graham MA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45, 880-886 (2005). • Systematic review of studies that determined the utility of combining an acetylcholine esterase inhibitor and an angiotensin receptor blocker (ARB) in the treatment of hypertension.
37. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 338, b1665 (2009).
38. Mann JFE, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 372, 547-553 (2008). • Analysis of renal outcomes in the Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events (ONTARGET) trial.
39. Uresin Y, Taylor AA, Kilo C et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J. Renin Angiotensin Aldosterone Syst. 8(4), 190-200 (2007). • One of the first large studies to evaluate the safety and efficacy of aliskiren in combination with an angiotensinconverting enzyme (ACE) inhibitor.
40. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 370, 221-229 (2007). • One of the first large studies to evaluate the safety and efficacy of aliskiren in combination with an ARB.
41. Chrysant SG, Murray AV, Hoppe UC et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr. Med. Res. Opin. 24, 1039-1047 (2008). • One of the first long-term studies to evaluate the safety and efficacy of aliskiren in combination with an ARB.
42. Solomon SD, Appelbaum E, Manning WJ et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119, 530-537 (2009). • Studies the effects of an ARB and ARB/ direct renin inhibitors combination on left ventricular hypertrophy in patients with hypertension.
43. Olsen MH, Wachtell K, Ibsen H et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J. Hypertens. 24, 775-781 (2006).
44. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am. J. Med. 122, 290-300 (2009).
45. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001). • First large-scale clinical trial to examine the benefit of adding an ARB to optimal therapy, including an ACE inhibitor, in chronic heart failure.
46. Pfeffer MA, McMurray JJV, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893-1906 (2003). • First large-scale clinical trial to compare an ARB, ACE inhibitor and their combination in patients with heart failure or left ventricular dysfunction after myocardial infarction.
47. McMurray JJV, Pitt B, Latini R et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1, 17-24 (2008). • Tested the safety of adding aliskiren to optimal therapy, including an ACE inhibitor, β-blocker, and spironolactone, in patients with heart failure.
48. Taylor AL, Ziesche S, Yancy C et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351, 2049-2057 (2004).
49. Pitt B, Zannad F, Remme WJ et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341, 709-717 (1999).
50. Hunt SA, Abraham WT, Chin MH et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119, e391-e479 (2009).
51. Phillips CO, Kashani A, Ko DKK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction. Arch. Intern. Med. 167, 1930-1936 (2007). • Examined the safety of combining an ACE inhibitor and ARB in patients with left ventricular dysfunction.
52. Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med. 351, 1941-1951 (2004).
53. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 285, 2719-2728 (2001).
54. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
55. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
56. Kunz R, Friedrich C, Wolbers M, Mann JFE. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148, 30-48 (2008).
57. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008). • First large study to assess the efficacy and safety of aliskiren when added to an ARB in subjects with diabetic nephropathy.
58. Anavekar NS, Gans DJ, Berl T et al. Predictors of cardiovascular events in patients with Type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int. 92(Suppl.), S50-S55 (2004).
59. Ruilope LM, Segura J. Losartan and other angiotensin II antagonists for nephropathy in Type 2 diabetes mellitus: a review of the clinical trial evidence. Clin. Ther. 25, 3044-3064 (2003).
60. Wilmer WA, Rovin BH, Hebert CJ, Rao SV, Kumor K, Hebert LA. Management of glomerular proteinuria: a commentary. J. Am. Soc. Nephrol. 14, 3217-3232 (2003).
61. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin Invest. 116, 288-296 (2006).
62. Kunz R, Wolbers M, Glass T, Mann JF. The COOPERATE trial: a letter of concern. Lancet 371, 1575-1576 (2008).
63. Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J. Renin Angiotensin Aldosterone Syst. 10, 1-8 (2009).
64. Dahlöf B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359, 995-1003 (2002).
65. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325, 293-302 (1991).
66. Khan NA, Hemmelgarn B, Herman RJ et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 - therapy. Can. J. Cardiol. 25, 287-298 (2009).